Other common mutations, involving genes such as EGFR, ERBB2, KRAS, PTEN, and BRAF, were identified in 15.2, 9.1, 9.1, 9.1, and 3% of patients, respectively, and the related percentage was similar to a prior WES study performed in Chinese NSCLC patients (3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.